B-cell non-Hodgkin's lymphoma (NHL) is a heterogeneous lymphoid malignancy consisting of several histologic types. Alterations in proto-oncogenes caused by reciprocal chromosome translocations have been implicated in the etiology of specific histologic groups. In this study, we examined the contribution of the cell cycle inhibitor genes P15, P16, and P18 to pathogenesis in a large panel of 209 cytogenetically characterized B-cell NHL tumors representing varied histologic groups. We identified the homozygous deletion of P15 and P16 genes in 13 tumors from 12 patients, all belonging to diffuse large-cell histology; 10 had this diagnosis made on presentation, l had transformed from small lymphocytic LTERATIONS IN genes crucial for normal development and/or cellular differentiation have been implicated in the genesis of several types of tumors. In eukaryotes, orderly progression of cells through the cell cycle is controlled by a series of cyclin-dependent kinases (CDKs). The complex formed by CDK4 and D-type cyclins controls the passage of cells through G I
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Negative regulation of the cell cycle occurs at GI and G2 checkpoint^.^.^ The function of CDK4KDK6 complexes is inhibited by a number of proteins, ie, p15, p16, p18, and ply, encoded by genes P15, P16, P18, and P19, respectively.h.'o That CDK4/CDK6 inhibitors can be tumor-suppressor genes is supported by two sets of data." First, recent studies have shown germlineI2 and somatic alterations of P16 in several types of cancer,i3"s such as melanoma,'' esophageal squamous cell car~inoma,'~~'' non-small cell lung cancer,'' pancreatic adenoma,I9 bladder carcinoma,2" acute lymphoblastic leukemia,21-2b adult T-cell le~kemia,~'.'' and lymphoid transfonnation of chronic myelogenous le~kemia.~' Second, transfection of wild P16 into human glioma cells that lack endogenous P16 suppressed growth." P15, which shares considerable homology with P16 and is located adjacent to P16 at 9~21," is also capable of inhibiting cyclin D/CDK4 activity. This gene has been studied less intensively. None- theless, homozygous deletion of P15 with P16 has been reported in a few cases of acute leukemia.2'.26-28 Characteristic molecular abnormalities of dominantly acting oncogenes, ie, BCL1, BCLZ, BCL6, and cMYC, have been identified in specific histologic groups of B-cell nonHodgkin's lymphoma (NHL).32333 However, the contribution of tumor-suppressor genes to lymphoma genesis and/or progression has been less well ~tudied.'~ Because abnormalities of 9p have been reported in about 10% of NHL;' we examined the structure of the CDK4/CDK6 inhibitor genes P15, P16, and P18 in 209 tumors from various histologic groups of B-cell NHL by Southern blot analysis and polymerase chain reaction-single-strand conformation polymorphism analyses (PCR-SSCP) to determine whether somatic changes in these genes might contribute to lymphomagenesis and/or progression. Our study indicates that inactivation of P15 and P16 occurs through homozygous deletion.
MATERIALS AND METHODS
The 209 tumors examined in this study were collected between January 1989 and December 1994 for a comprehensive pathologic, immunologic, and genetic evaluation of NHL. Cytogenetic studies were performed on lymphocytes prepared by mincing the fresh tumor biopsies in RPMI 1640 and cultured overnight in RPMI 1640 supplemented with 15% fetal bovine serum, 1% L-glutamine, and 1% penstrep. Standard air-dried chromosome spreads were trypsin-Giemsa banded and karyotypes were characterized following ISCN 1991 .' & Southern blot analysis. High molecular weight DNA was prepared from tissues frozen in liquid nitrogen. DNA was digested with Hind11 and BglII restriction enzymes, electrophoresed in 0.8% agarose-TBE gels, and blotted to nylon. Probes used in hybridization were a 2.0-kb cDNA fragment covering the coding region of P15:' an 800-bp cDNA fragment covering the coding region of P16' (both probes were a generous gift from Dr D. Beach, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), a 525-bp cDNA probe COV- ering the coding region of PI 8,7 and a 600-bp genomic DNA probe for BCL-1.'7 Probe DNA fragments were labeled with a-'*P-dCTP by random priming. Blots were hybridized for 16 hours to 20 hours at 6YC, washed in 0.1% sodium dodecyl sulfate (SDS) and 0.1 X SSC at the same temperature, and autoradiographed as described previously." PCR-SSCP. For PCR-SSCP analysis of P15, the following primer pairs were used: P15-1, 5'-GAGGACTCCGCGACGGTC-CC-3'1S"TGGGCTCAGCTTACCCT"; PIS-2, 5"AGG- For PCR-SSCP analysis of P18, the following primer pairs were used: P18-1, at 95°C and chilling on ice for 5 minutes, 2 to 3 pL of each sample was electrophoresed through 6% polyacrylamide gel with 10% glycerol at 8 to 10 W for 16 to 20 hours at room temperature. Dried gels were autoradiographed for 8 to 12 hours. Direct sequencing of PCR-arnpl$ed DNA. Tumor samples that showed abnormal conformation in PCR-SSCP were sequenced by the dideoxy chain termination method using an AmpliCycle sequencing kit (Perkin Elmer, Branchburg, NJ). In brief, about 500 ng of tumor DNA was amplified without isotope, as described above. PCR product was purified through Wizard PCR prep spin column (Promega, Madison, WI). About 2 pmol of y-"PdATP-labeled primer was mixed with about 10 ng of template DNA and sequenced following the manufacturer's instructions.
RESULTS
We examined the structure of P15, P16, and P18 genes in 209 B-cell NHLs of low-grade to high-grade histologies (Table 1) using Southern blot analysis, PCR-SSCP analysis, and direct sequencing. All these tumors were characterized by histology, immunophenotypic analysis, immunogenotypic analysis, and cytogenetic analysis. p16INK4* (MTSI,CDKN2). Southern blot analysis using a full-length cDNA probe did not identify any genomic rearrangements within this gene. Homozygous loss of this gene was identified in 13 tumors from 12 patients with diffuse large-cell lymphoma but not in tumors of other histologic groups. One patient showed histologic progression from small lymphocytic lymphoma to diffuse large-cell lymphoma. Material was not available from the initial tumor; therefore, it is not known whether the deletion was present at this stage. In a second patient, histologic progression occurred from Hodgkin's disease (HD) to diffuse large-cell lymphoma. In this patient, HD tissue showed normal P16, whereas deletion was present in the lymphoma. The remaining 10 patients presented with diffuse large-cell lymphoma de novo. Repeat studies using probes for P16 and BCLl genes hybridized simultaneously showed normal hybridization with BCLl probe in tumors that showed no hybridization or very weak hybridization with P16 probe. These results indicate that the DNA was intact in these tumors and lack of hybridization with p16 probe was due to loss of this gene in tumor cells (Fig 1A) . In three of these tumors (1399,2590, and 3610), P16 and P15 probes showed very weak hybridization that was probably due to hybridization to DNA from nontumor cells present in them. In one case (2590/3499), deletion was identified in tumor obtained at diagnosis and after therapeutic relapse. PCR-SSCP analysis did not detect any tumor-related changes in the P16. An abnormal conformation in PCR-SSCP was identified in seven patients with exon 2 primers. Sequence analysis showed a G to A transition at codon 140 (GCG"'""" -P phism."
were stripped off and the blots were rehybridized with a P15 cDNA probe. No gross alterations were detected in this gene in any tumor. However, absence of hybridization or very weak hybridization indicating deletion of this gene was observed in the 13 tumors (Fig lB) , all of which showed deletion of P16. PCR-SSCP analysis did not identify any tumorrelated changes in the coding region of P15. An abnormal conformation in PCR-SSCP was identified with primer set two in four patients (1.7%). Nucleotide sequence analysis showed a transition from G to A at nucleotide 240 located 88 bp upstream of the first codon (data not shown).
P18. Hybridized P15 probe was stripped off and the blots were rehybridized with a cDNA probe for P18. No genomic alterations were detected in this gene in any tumor. A polymorphic alteration in the PCR-SSCP pattern in exon 2 was identified in 19% of patients. Sequence analysis showed a C to T transition (GGCg'yci"e -P GGTglyci"") at codon 114 (data not shown).
Cytogenetic changes. Among the 209 tumors included in this study, cytogenetic study was not performed on 20 tumors because of insufficient material. Metaphase spreads of suitable quality for cytogenetic analysis were not obtained from 35 tumors, and only normal metaphase spreads were observed in 9 tumors. Clonal cytogenetic abnormalities were identified in the remaining 145 tumors (Table 1) . Specific recumng translocations affecting the site of cMYC (8q24), BCLl/F'RADl/CYCLIN Dl (llq13), BCL2 (18q21), or BCL6 (3q27) were identified in 52% of the cytogenetically abnormal tumors. Structural cytogenetic changes affecting 9p21 to which P15 and P16 have been mapped were identified in 9 tumors. These tumors were hemizygous for part of the short arm of chromosome 9 distal to band p13 due to the formation of a derivative chromosome 9p or, in one case, due to deletion. However, only one such tumor (3610) showed deletion of P15 and P16. In contrast to these findings, ACGthrmnine. , (data not shown), which is a known polymor-
p 1 5 I N K 4 B (MTS2). Hybridized P16 and BCLl probes
For personal use only. on October 27, 2017. by guest www.bloodjournal.org From chromosome 9p appeared to be cytogenetically normal in the remaining 12 tumors that showed deletion of p15 and p16. Four of the 13 tumors with a deleted P15 and P16 had t( 11; 14)(q13;q32) ( Table 2) .
Structural cytogenetic abnormality affecting lp32 to which P18 has been mapped was identified in 13 tumors.
These tumors were hemizygous for part of short arm of chromosome l distal to band p32 due to deletion (5 tumors), to a derivative chromosome l p (6 tumors), or to monosomy (2 tumors). However, no changes in P18 were identified.
DISCUSSION
Alterations in specific proto-oncogenes located at sites of specific translocation breaks have been implicated in the genesis of different histologic types of NHL.3z,33 Chromosome regions lp, 6q, 7p, 7q, 9p, llq, 14q, and 17p have been identified as recurrent sites of deletions or structural
The pathologic significance of these secondary recurrent cytogenetic abnormalities has been little studied in NHL. Alterations in the p53 gene, a gene involved in cell cycle regulation,'" have been reported in a few cases of transformed NHL,42-44 whereas two distinct sites of molecul a r deletions, probably harboring tumor-suppressor genes, have been identified in 6q deleti0ns.4~ Therefore, we made a comprehensive study of CDK4 inhibitor genes P15 and P16, located at 9p21, and CDK6 inhibitor gene P18, located at lp32, in cytogenetically characterized primary B-cell NHL.
Homozygous deletion of P15 and P16 was found in 15% of diffuse large-cell NHL. In three of these tumors (1399, 2590, and 3610), P15 and P16 probes gave very weak signal. Because the intensity of signal appeared to be less than 50% of that from the control probe (BCL1 probe), it is assumed that the weak signal of P15 and P16 probes was due to hybridization to DNA from the contaminating normal cells. This is supported by the fact that, in these three tumors, 45% to 60% of metaphases analyzed showed normal karyotype. However, hemizygous loss of these genes cannot be completely ruled out. No point mutations were identified in the coding regions of these genes. Cytogenetic analysis showed apparently normal 9p21 in 12 of the 13 tumors that showed deletion of the genes indicating the presence of a molecular deletion at 9p21 in them. Because no rearranged DNA band was seen on Southern blots of these tumors, it is assumed that DNA breaks leading to deletion have occurred on 9p21 outside P15 and P16. On the other hand, cytogenetic hemizygosity for 9p was observed in 9 tumors (1 I %), but P I5 and P16 showed normal structure on Southern blots.
PCR-SSCP analysis of the coding regions of these genes did not detect tumor-related changes in B-cell NHLs. The abnormal conformation patterns identified were due to a polymorphism at nucleotide 240 in the 5"noncoding region of P15 and a polymorphism at codon 140 of P16. Absence of P15 and P16 deletions in NHLs of low-and intermediategrade histologies indicate that these deletions in P15 and P16 are associated with aggressive disease.
Including tumors that were hemizygous for Ip, no gross alterations or deletions or mutational changes were identified in P18. A polymorphism at codon 114 was identified.
The frequency of P15 and P16 deletions now found was higher than that reported in three previous ~t u d i e s .~~*~~" * These studies reported deletion of P16 in 2 of the 84 tumors examined. One of these was a case of transformed NHL, and the second was a case of NHL in a leukemic phase.% However, the lack of histologic subclassification of tumors examined in earlier studies, particularly separation into low and high grades of malignancy, precludes comparison with our findings.
Recently, several investigators have examined the structure of P15 and/or P16 in several types of primary leukemias, including acute lymphoblastic leukemia (ALL) of B cells and T cells, T-cell prolymphocytic leukemia, adult T-cell leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia (AML), myelodysplastic syndrome, and myeloproliferative disorders. Homozygous deletion, primarily of P16, has been identified in 64 of 142 T-cell ALL, 44 of 224 B-cell ALL, 10 of 37 adult T-cell leukemia, 5 of 10 chronic myelogenous leukemia in lymphoid blast crisis, and in 1 of 1 1 1 AML. Structural reFor personal use only. on October 27, 2017. by guest www.bloodjournal.org From Hindlll-and Bgl Il-digested DNA from diffuse largecell lymphomas simultaneously hybridized with probes for P16 and BCL-l. The probe for P16 showed no or very weak hybridization (indicated by arrowheads), whereas the probe for BCL-l showed strong hybridization (indicated by arrows). These results suggest homozygous deletion of P16 in these tumors. Open arrows indicate a rearranged DNA band identified by BCL-1 probe in this tumor. The positions of size marker DNA fragments ( h DNA digested with Hindlll) is shown on the left side. DNA from human placenta (P) and a diffuse lymphoma (2218) was used as negative controls. (B). The above-mentioned probes were stripped off and the blot was hybridized with a probe for P15. Note the absence or very weak hybridization of the probe, suggesting homozygous deletion of P15. Whether deletions of P15 and P16 occur early in disease or during progression is not known. A few studies examined sequential tumor samples. In one study of CML:9 deletion of P16 was found only in lymphoid blast crisis but not in the chronic phase. Fizzotti et al'? found P16 deletions at diagnosis and at relapse in two patients with ALL. Hatta et al" noticed that disease progressed rapidly to acute phase in a patient who had deletion of P16 at chronic phase. In a second patient, P15 and P16 were normal in the chronic phase but deleted at acute phase. In two cases of NHL in which sequential samples were examined, P16 deletions occurred with transformation to immunoblastic lymphoma. 24 In contrast to these findings, 10 of our 12 patients with deletion of P15 and P16 presented with diffuse large-cell lymphoma de novo. These data suggest that deletion of P15 and/or P16 region at 9p21 might contribute to lymphomagenesis in this subset of NHL.
For personal use only. on October 27, 2017. by guest www.bloodjournal.org From The above data indicate that loss of both alleles of P15
and P16 is the principal mechanism of inactivation of these genes when this occurs in primary leukemias and lymphomas. This is in contrast to the findings in P53 and Rb genes, whose inactivation is associated with deletion of one allele and mutation in the second allele. Because the occurrence of 9p21 abnormalities does not correlate with changes in P15/P16, it remains possible that this chromosome site may contain other genes of importance in oncogenesis.
